Evidence map›Paper›PMID 37405480›Full record

ReviewMedical oncology (Northwood, London, England)2023

Impact of exosome therapy on pancreatic cancer and its progression.

Mohamed El-Tanani, Hamdi Nsairat, Ismail I Matalka, Alaa A A Aljabali, Vijay Mishra, Yachana Mishra, Gowhar A Naikoo, Sai Raghuveer Chava, Nitin B Charbe, Murtaza M Tambuwala

Open access · hybridAbstract readReview
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Emerging biomarkers for pancreatic cancer: from early detection to personalized therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 6 countries.

Mohamed El-TananiPharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, 19328, Jordan. m.tanani@ammanu.edu.jo.
Hamdi NsairatPharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, 19328, Jordan.
Ismail I MatalkaRas Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE.
Alaa A A AljabaliDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid, 21163, Jordan.
Vijay MishraSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, India.
Yachana MishraDepartment of Zoology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, 144411, India.
Gowhar A NaikooDepartment of Mathematics and Sciences, College of Arts and Applied Sciences, Dhofar University, PC 211, Salalah, Oman.
Sai Raghuveer ChavaDepartment of Chemistry, Texas A&M University, Kingsville, TX, USA.
Nitin B CharbeDepartment of Pharmaceutics, College of Pharmacy, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL, USA.
Murtaza M TambuwalaLincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln, LN6 7TS, UK. mtambuwala@lincoln.ac.uk.ORCID http://orcid.org/0000-0001-8499-9891
Al-Ahliyya Amman University · JOLovely Professional University · INDhofar University · OMJordan University of Science and Technology · JOTexas A&M University – Kingsville · USUniversity of Florida · USUniversity of Lincoln · GBYarmouk University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer, one of the most aggressive tumors, has a dismal prognosis because of the low rates of early identification, fast progression, difficulties following surgery, and the ineffectiveness of current oncologic therapies. There are no imaging techniques or biomarkers that can accurately identify, categorize, or predict the biological behavior of this tumor. Exosomes are extracellular vesicles that play a crucial rule in the progression, metastasis, and chemoresistance of pancreatic cancer. They have been verified to be potential biomarkers for pancreatic cancer management. Studying the role of exosomes in pancreatic cancer is substantial. Exosomes are secreted by most eukaryotic cells and participated in intercellular communication. The components of exosomes, including proteins, DNA, mRNA, microRNA, long non-coding RNA, circular RNA, etc., play a crucial role in regulating tumor growth, metastasis, and angiogenesis in the process of cancer development, and can be used as a prognostic marker and/or grading basis for tumor patients. Hereby, in this concise review, we intend to summarize exosomes components and isolation, exosome secretion, function, importance of exosomes in the progression of pancreatic cancer and exosomal miRNAs as possible pancreatic cancer biomarkers. Finally, the application potential of exosomes in the treatment of pancreatic cancer, which provides theoretical supports for using exosomes to serve precise tumor treatment in the clinic, will be discussed.

Indexed as

ExosomesMicroRNAsPancreatic NeoplasmsBiomarkers, TumorHumansBiomarkers, TumorMicroRNAsBiomarkersExosomesFolfirinoxGemcitabineIntercellular communicationPancreatic cancer

Identifiers

PMID37405480
PMCPMC10322774
OpenAlexW4383187579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.